$58.26
3.37% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Verona Pharma plc Sponsored ADR Stock price

$60.29
-5.68 8.61% 1M
+31.58 110.00% 6M
+13.85 29.82% YTD
+44.36 278.47% 1Y
+55.35 1,120.45% 3Y
+56.32 1,418.64% 5Y
+46.79 346.59% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.75 2.99%
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Key metrics

Market capitalization $5.10b
Enterprise Value $4.83b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 114.88
P/S ratio (TTM) P/S ratio 121.48
P/B ratio (TTM) P/B ratio 24.94
Revenue (TTM) Revenue $42.00m
EBIT (operating result TTM) EBIT $-154.94m
Free Cash Flow (TTM) Free Cash Flow $-122.83m
Cash position $399.76m
EPS (TTM) EPS $-2.16
P/E forward 549.76
P/S forward 16.27
EV/Sales forward 15.39
Short interest 12.08%
Show more

Is Verona Pharma plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy
100%

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
42 42
-
100%
- Direct Costs 3.63 3.63
434% 434%
9%
38 38
5,743% 5,743%
91%
- Selling and Administrative Expenses 148 148
200% 200%
351%
- Research and Development Expense 45 45
157% 157%
106%
-154 -154
129% 129%
-366%
- Depreciation and Amortization 1.06 1.06
56% 56%
3%
EBIT (Operating Income) EBIT -155 -155
128% 128%
-369%
Net Profit -174 -174
218% 218%
-413%

In millions USD.

Don't miss a Thing! We will send you all news about Verona Pharma plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verona Pharma plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
6 days ago
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repay...
Neutral
Seeking Alpha
about one month ago
Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operat...
Neutral
GlobeNewsWire
about one month ago
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO David Zaccardelli
Employees 209
Founded 2005
Website www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today